140 related articles for article (PubMed ID: 38135609)
21. Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation.
Correa DD; Braun E; Kryza-Lacombe M; Ho KW; Reiner AS; Panageas KS; Yahalom J; Sauter CS; Abrey LE; DeAngelis LM; Omuro A
J Neurooncol; 2019 Sep; 144(3):553-562. PubMed ID: 31377920
[TBL] [Abstract][Full Text] [Related]
22. High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom.
Kassam S; Chernucha E; O'Neill A; Hemmaway C; Cummins T; Montoto S; Lennard A; Adams G; Linton K; McKay P; Davies D; Rowntree C; Easdale S; Eyre TA; Marcus R; Cwynarski K; Fox CP
Bone Marrow Transplant; 2017 Sep; 52(9):1268-1272. PubMed ID: 28581466
[TBL] [Abstract][Full Text] [Related]
23. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study.
Houillier C; Dureau S; Taillandier L; Houot R; Chinot O; Moluçon-Chabrot C; Schmitt A; Gressin R; Choquet S; Damaj G; Peyrade F; Abraham J; Delwail V; Gyan E; Sanhes L; Cornillon J; Garidi R; Delmer A; Al Jijakli A; Morel P; Waultier A; Paillassa J; Chauchet A; Gastinne T; Laadhari M; Plissonnier AS; Feuvret L; Cassoux N; Touitou V; Ricard D; Hoang-Xuan K; Soussain C;
J Clin Oncol; 2022 Nov; 40(32):3692-3698. PubMed ID: 35834762
[No Abstract] [Full Text] [Related]
24. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
[TBL] [Abstract][Full Text] [Related]
25. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system.
Illerhaus G; Müller F; Feuerhake F; Schäfer AO; Ostertag C; Finke J
Haematologica; 2008 Jan; 93(1):147-8. PubMed ID: 18166803
[TBL] [Abstract][Full Text] [Related]
26. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma.
Alvarnas JC; Negrin RS; Horning SJ; Hu WW; Long GD; Schriber JR; Stockerl-Goldstein K; Tierney K; Wong R; Blume KG; Chao NJ
Biol Blood Marrow Transplant; 2000; 6(3A):352-8. PubMed ID: 10905773
[TBL] [Abstract][Full Text] [Related]
27. Challenges in the management of primary central nervous system lymphoma.
Sun X; Lv L; Wu Y; Cui Q; Sun S; Ji N; Liu Y
Crit Rev Oncol Hematol; 2023 Aug; 188():104042. PubMed ID: 37277008
[TBL] [Abstract][Full Text] [Related]
28. Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
Asghar N; Masood A; Dhaliwal A; Khurana S; Davis J; Hashmi H; Husnain M
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):15-21. PubMed ID: 36328891
[TBL] [Abstract][Full Text] [Related]
29. Long-term survival after salvage pemetrexed for refractory primary T-cell lymphoma of the CNS.
Liu A; Alalami H; Fan X; Patil C; Gill JM; Kesari S; Hu J
CNS Oncol; 2023 Sep; 12(3):CNS100. PubMed ID: 37435740
[TBL] [Abstract][Full Text] [Related]
30. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
31. A single-center retrospective analysis of outcome measures and consolidation strategies for relapsed and refractory primary CNS lymphoma.
Bonm AV; Gibson AW; Holmberg LA; Mielcarek M; McGranahan T; Taylor LP; Graber JJ
J Neurooncol; 2021 Jan; 151(2):193-200. PubMed ID: 33398532
[TBL] [Abstract][Full Text] [Related]
32. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.
Cheng T; Forsyth P; Chaudhry A; Morris D; Glück S; Russell JA; Stewart DA
Bone Marrow Transplant; 2003 Apr; 31(8):679-85. PubMed ID: 12692608
[TBL] [Abstract][Full Text] [Related]
33. Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant.
Puckrin R; Chua N; Shafey M; Stewart DA
Leuk Lymphoma; 2022 Oct; 63(10):2444-2452. PubMed ID: 35459424
[TBL] [Abstract][Full Text] [Related]
34. High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry.
Kondo E; Ikeda T; Izutsu K; Chihara D; Shimizu-Koresawa R; Fujii N; Sakai T; Kondo T; Kubo K; Kato Y; Akasaka T; Fukuda T; Ichinohe T; Atsuta Y; Suzumiya J; Suzuki R;
Biol Blood Marrow Transplant; 2019 May; 25(5):899-905. PubMed ID: 30664936
[TBL] [Abstract][Full Text] [Related]
35. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB
Cancer; 2017 Aug; 123(16):3073-3079. PubMed ID: 28369839
[TBL] [Abstract][Full Text] [Related]
36. A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma.
Steffanoni S; Calimeri T; Anzalone N; Mastaglio S; Bernardi M; Ferreri AJ
Expert Rev Hematol; 2022 Jan; 15(1):33-43. PubMed ID: 34904506
[TBL] [Abstract][Full Text] [Related]
37. Consolidation Therapy in Primary Central Nervous System Lymphoma.
Kim P; Omuro A
Curr Treat Options Oncol; 2020 Jul; 21(9):74. PubMed ID: 32725379
[TBL] [Abstract][Full Text] [Related]
38. Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases.
Soussain C; Choquet S; Fourme E; Delgadillo D; Bouabdallah K; Ghesquières H; Damaj G; Dupriez B; Vargaftig J; Gonzalez A; Houillier C; Taillandier L; Hoang-Xuan K; Leblond V
Haematologica; 2012 Nov; 97(11):1751-6. PubMed ID: 22581000
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.
Cohen YI; Lebel E; Zimran E; Shaulov A; Stepensky P; Grisariu S; Avni B
Transplant Cell Ther; 2023 Aug; 29(8):505.e1-505.e8. PubMed ID: 37160229
[TBL] [Abstract][Full Text] [Related]
40. Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients - the randomized phase III PRIMA-CNS trial.
Isbell LK; Uibeleisen R; Friedl A; Burger E; Dopatka T; Scherer F; Orban A; Lauer E; Malenica N; Semenova I; Vreden A; Valk E; Wendler J; Neumaier S; Fricker H; El Rabih AAH; Gloggengießer C; Hilbig D; Bleul S; Weis J; Gmehlin D; Backenstrass M; Wirtz S; Ihorst G; Finke J; Illerhaus G; Schorb E
BMC Cancer; 2023 Aug; 23(1):767. PubMed ID: 37596517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
